Navigation Links
New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
Date:11/21/2008

New data presented at the 61st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA™ (sitagliptin), a diabetes medicine from Merck & Co., Inc., significantly reduced blood sugar levels in elderly patients with type 2 diabetes and was not associated with hypoglycemia (low blood sugar). In this study of 206 patients aged 65 to 96 years, there were no reports of hypoglycemia in either the JANUVIA or the placebo groups. Advanced age contributes to the risk of hypoglycemia.

NATIONAL HARBOR, Md. (Business Wire EON) November 21, 2008 -- JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin. JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis and angioedema. As is typical with other anti-hyperglycemic agents used in combination with a sulfonylurea, when JANUVIA is used in combination with a sulfonylurea, a class of medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia.

"The elderly population presents challenges for the treatment of type 2 diabetes, as various factors can affect the ability to lower these patients' blood sugar to target levels," said lead study investigator Nir Barzilai, M.D., director of the Institute for Aging Research and Animal Physiology Core, Diabetes Research Training Center at the Albert Einstein College of Medicine. "In this study, JANUVIA effectively helped lower blood glucose levels and was not associated with hypoglycemia."

JANUVIA significa
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
2. Landmark study defines benefits of early HIV testing and treatment for infected infants
3. Study identifies causes of bone loss in breast cancer survivors
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
6. Rutgers researchers study cites media violence as critical risk factor for aggression
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
9. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
10. Study investigates Gore-tex-type device to stop strokes and mini-strokes
11. The smart way to study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 
(Date:5/19/2013)... Utah (PRWEB) May 19, 2013 ... on small business health insurance . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and the self-employed intrinsically know the value of ...
(Date:5/19/2013)... The report “Feed Additives Market by ... up to 2017” published by MarketsandMarkets, defines and segments ... forecasting of the global volume and revenue for the ... restraining factors for the global market with analysis of ... market is segmented and revenue is forecasted on the ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients with ... increase the chance of a healthier smile. Laser gum ... not only removes diseased gum tissue in patients, but it ... dental implants. , LANAP uses a laser to ... help stimulate the healthy tissue as well as encourage new ...
(Date:5/19/2013)... Exciting new Skin Brushes are available from ... practice known through the ages but is a lost ... brushing, has so many benefits for our health and ... love that circulation and lymphatic systems get a boost ... is supported through Skin Brushing." , Why is Skin ...
(Date:5/19/2013)... Vedra Beach, Florida (PRWEB) May 19, 2013 ... value and market access, is pleased to unveil a ... trade show environment that provides a powerful array of ... to partners in the US and abroad. , HE-Xpo ... and will offer attendees the look and feel of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... Institute scientists, discovery of a cancer-causing gene the first ... how the panoramic view of genomics and the close-up perspective ... involved in cancer and which are mere bystanders. The findings ... Nature . "In the coming years, we can ...
... , ROCHESTER, Minn., June 24 The Mayo Clinic ... collaborative symposium on innovations in health care experience and ... open to the public. It will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
... finds , WEDNESDAY, June 24 (HealthDay News) -- Monitoring ... drugs to prevent osteoporosis is unnecessary and could be ... researchers analyzed data from a large randomized trial that ... used bisphosphonate) in more than 6,000 postmenopausal women with ...
... Furthering its mission to improve the quality of ... signed a cooperative agreement with nine countries belonging ... In a drive to strengthen capacities and certification ... from Cambodia, Laos, Myanmar, Singapore, Vietnam, Indonesia, Malaysia, ...
... ... Services , ... Francisco, CA (PRWEB) June 24, 2009 -- Today, Quantros announced the launch of a ... Quantros IT Consulting Services provides a cost-effective and reliable model for creating and supporting ...
... "Superfruit" Beverages Expand Beverages Holdings, Wholesome Offerings , , ... of the Sunny Delight Beverages Co., Veryfine Co. and The ... all the assets of Bossa Nova Beverage Group, Inc., a ... beverage category with its original acai juice . ...
Cached Medicine News:Health News:Study pinpoints novel cancer gene and biomarker 2Health News:Study pinpoints novel cancer gene and biomarker 3Health News:Study pinpoints novel cancer gene and biomarker 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Bone Therapy May Not Always Need Monitoring 2Health News:Goal of good quality medicines advanced by new USP agreement with 9 ASEAN countries 2Health News:Quantros Establishes IT Consulting Services Business Unit 2Health News:Quantros Establishes IT Consulting Services Business Unit 3Health News:Beverages Holdings, LLC Acquires Bossa Nova: The Superfruit Company 2Health News:Beverages Holdings, LLC Acquires Bossa Nova: The Superfruit Company 3
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: